<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3591">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01761643</url>
  </required_header>
  <id_info>
    <org_study_id>CCTG 595</org_study_id>
    <nct_id>NCT01761643</nct_id>
  </id_info>
  <brief_title>CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM</brief_title>
  <official_title>CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City of Long Beach Department of Health and Human Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>California HIV/AIDS Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CCTG 595 is a controlled, open-label, two-arm, randomized (1:1) clinical demonstration&#xD;
      project to determine if the use of a text-message based adherence intervention (iTAB)&#xD;
      improves retention and adherence to PrEP compared to standard of care (SoC) PrEP delivery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 400 HIV-uninfected men who have sex with men (MSM)and male to female (M to F)&#xD;
      transgender individuals with recent high-risk transmission behavior will be enrolled into the&#xD;
      study. Each subject will be followed for up to 48 weeks after enrollment of the last subject.&#xD;
      The primary endpoint will be measured at 48 weeks.&#xD;
&#xD;
      All subjects will start PrEP with TDF + FTC fixed dose combination given once daily. Subjects&#xD;
      will be randomized (1:1) to either the iTAB text messaging adherence reminder intervention&#xD;
      with SoC or the SoC alone arm. Subjects placed into the iTAB intervention arm will receive a&#xD;
      personalized, automated texting system to maintain adherence and retention. Both groups will&#xD;
      receive access to PrEP in accordance with standardized comprehensive methods of prescribing,&#xD;
      risk reduction counseling, adherence counseling, and clinical assessments that include safety&#xD;
      monitoring, as well as HIV and STD screening.&#xD;
&#xD;
      TDF 300 mg + FTC 200 mg fixed dose combination will be given orally once daily starting at&#xD;
      the baseline visit (month 0) and continued throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2012</start_date>
  <completion_date type="Actual">July 11, 2018</completion_date>
  <primary_completion_date type="Actual">June 13, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The purpose of this study is to evaluate a promising method of reinforcing PrEP adherence using text message. In this study, we will hope to learn if text message reminders increase PrEP adherence.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Group 1: PrEP daily, HIV/STI screening, adherence and risk behavior counseling, and safety monitoring Group 2: PrEP daily, HIV/STI screening, adherence and risk behavior counseling, and safety monitoring as well as iTAB text adherence reminders</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to PrEP</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Proportion of participants adherent to PrEP as measured by TFV-DP dried blood spot (DBS) concentrations &gt; 719 fmol/punch at Week 12 and the last on-drug visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perfect Adherence to PrEP</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>Proportion of participants with perfect adherence to PrEP as measured by TFV-DP dried blood spot (DBS) concentrations &gt; 1246 fmol/punch at Week 12 and the last on-drug visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of HIV Seroconversion</measure>
    <time_frame>Up to 2.5 years after baseline</time_frame>
    <description>Determine the rate of HIV seroconversion in PrEP users and compare the iTAB to SOC arms for number of new infections as a proportion at 48 weeks and end of study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">398</enrollment>
  <condition>Patient Adherence</condition>
  <condition>HIV Seronegativity</condition>
  <arm_group>
    <arm_group_label>Standard of Care (SoC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This proposal will perform a study of potential methods to improve adherence and retention by evaluating standard procedures versus the use of the iTAB platform.&#xD;
All subjects will receive SoC that will include health education, clinical assessments, laboratory safety monitoring, STI and HIV screening, HIV risk reduction counseling, assessment of psycho-social barriers, adherence counseling, and completion of a computer based survey.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SoC + iTab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.&#xD;
Subjects will have visits with the study coordinator to introduce the iTAB texting system.&#xD;
Once the time is identified, the text reminder system is automated. Patients will confirm medication taking via text responses to the personalized reminders. If a participant does not respond on three consecutive occasions, a high alert message (chosen by the participant) will be sent. If the subject does not respond to this message, the study coordinator would initiate phone calls to contact the subject and explore barriers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SoC + iTab</intervention_name>
    <description>Text messaging reminders to improve adherence to PrEP</description>
    <arm_group_label>SoC + iTab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or transgender M to F who has sex with men.&#xD;
&#xD;
          -  Age 18 years or older.&#xD;
&#xD;
          -  Subjects must have substantial ongoing risk of acquisition of HIV as evident by one or&#xD;
             more of the following:&#xD;
&#xD;
               -  Has at least one HIV infected sexual partner for ≥4 weeks.&#xD;
&#xD;
               -  No condom use during anal intercourse with ≥3 male sex partners who are&#xD;
                  HIV-positive or of unknown HIV status during the last 3 months.&#xD;
&#xD;
               -  No condom use during anal sex with ≥1 male partner and STI diagnosis during the&#xD;
                  last 3 months.&#xD;
&#xD;
          -  Negative for HIV infection by rapid HIV test and confirmed negative by NAT or other&#xD;
             sensitive method such as antibody- antigen test.&#xD;
&#xD;
          -  Acceptable laboratory values in the past 30 days:&#xD;
&#xD;
               -  Calculated creatinine clearance of at least 60 mL/min by the Cockcroft-Gault&#xD;
                  formula (eCcr (male) in mL/min = [(140 - age in years) x (lean body weight in&#xD;
                  kg)] / (72 x serum creatinine in mg/dL)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and/ or aspartate aminotransferase (AST) &lt; 3 x&#xD;
                  upper limit of normal (ULN)&#xD;
&#xD;
               -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 750/ mm3&#xD;
&#xD;
               -  Platelets &gt; 75,000/ mm3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to give informed consent.&#xD;
&#xD;
          -  Active hepatitis B (positive hepatitis B surface antigen (HBSAg) or HBSAg negative/ HB&#xD;
             core antibody positive/ HBV PCR positive).&#xD;
&#xD;
          -  Has substantial medical condition, that in the opinion of the investigator would&#xD;
             preclude participation, as defined by&#xD;
&#xD;
               -  cardiovascular condition that may lead to an increased risk of complication if&#xD;
                  placed on study drugs.&#xD;
&#xD;
               -  gastrointestinal condition that would impair absorption of study drugs.&#xD;
&#xD;
               -  neurological or psychiatric condition that would significantly impair the ability&#xD;
                  to adhere to PrEP.&#xD;
&#xD;
               -  calculated GFR &lt; 60 mL/min.&#xD;
&#xD;
               -  alcohol or drug abuse or dependence that would significantly impair the ability&#xD;
                  to adhere to PrEP (only for those with severe impairment).&#xD;
&#xD;
               -  other medical condition that would unacceptably increase the risk of harm from&#xD;
                  study drug or significantly impair the ability to adhere to PrEP.&#xD;
&#xD;
          -  Suspected sensitivity or allergy to the study drug or any of its components.&#xD;
&#xD;
          -  Currently using an essential product or medication that interacts with the study drug&#xD;
             such as the following:&#xD;
&#xD;
               -  ART (including nucleoside analogs, non-nucleoside reverse transcriptase&#xD;
                  inhibitors, protease inhibitors or investigational antiretroviral agents)&#xD;
&#xD;
               -  Agents with known nephrotoxic potential:&#xD;
&#xD;
                    -  aminoglycoside antibiotics (including gentamicin)&#xD;
&#xD;
                    -  IV amphotericin B&#xD;
&#xD;
                    -  cidofovir&#xD;
&#xD;
                    -  cisplatin&#xD;
&#xD;
                    -  foscarnet&#xD;
&#xD;
                    -  IV pentamidine&#xD;
&#xD;
                    -  IV vancomycin&#xD;
&#xD;
                    -  oral or IV gancyclovir&#xD;
&#xD;
                    -  other agents with significant nephrotoxic potential&#xD;
&#xD;
               -  Drugs that slow renal excretion&#xD;
&#xD;
                    -  Probenecid&#xD;
&#xD;
               -  Immune system modulators&#xD;
&#xD;
                    -  Systemic chemotherapeutic agents (i.e. cancer treatment medications)&#xD;
&#xD;
                    -  Ongoing systemic corticosteroids (with the exception of short courses of&#xD;
                       tapering steroid doses for asthma or other self- limited condition).&#xD;
&#xD;
                    -  Interleukin-2 (IL-2)&#xD;
&#xD;
                    -  Interferon (alpha, beta, or gamma)&#xD;
&#xD;
               -  Other agent known to have a significant interaction with TDF or FTC&#xD;
&#xD;
               -  Proteinuria 2+ or greater by urine dipstick&#xD;
&#xD;
               -  Signs or symptoms suggestive of acute HIV infection&#xD;
&#xD;
               -  Any other reason or condition that in the opinion of the investigator would&#xD;
                  interfere with participation, complicate interpretation of study outcome data, or&#xD;
                  otherwise interfere with achieving the study objectives.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheldon Morris, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CCTG, UCSD AVRC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Moore, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CCTG, UCSD HNRP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Long Beach Department of Health and Human Services</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 2, 2013</study_first_submitted>
  <study_first_submitted_qc>January 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2013</study_first_posted>
  <results_first_submitted>May 13, 2020</results_first_submitted>
  <results_first_submitted_qc>May 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2020</results_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Sheldon Morris</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>PrEP</keyword>
  <keyword>Pre exposure Prophylaxis</keyword>
  <keyword>Text Messaging</keyword>
  <keyword>Truvada</keyword>
  <keyword>iTab</keyword>
  <keyword>CCTG</keyword>
  <keyword>595</keyword>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT01761643/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT01761643/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care (SoC)</title>
          <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC)</description>
        </group>
        <group group_id="P2">
          <title>SoC + iTab</title>
          <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC) and daily individualized text-messaging for adherence building (iTAB)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care (SoC)</title>
          <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC)</description>
        </group>
        <group group_id="B2">
          <title>SoC + iTab</title>
          <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC) and daily individualized text-messaging for adherence building (iTAB)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="198"/>
            <count group_id="B2" value="200"/>
            <count group_id="B3" value="398"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.4" spread="8.7"/>
                    <measurement group_id="B2" value="35.1" spread="9.8"/>
                    <measurement group_id="B3" value="35.2" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Transgender woman</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic ethnicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PREP use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adherence to PrEP</title>
        <description>Proportion of participants adherent to PrEP as measured by TFV-DP dried blood spot (DBS) concentrations &gt; 719 fmol/punch at Week 12 and the last on-drug visit.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Only participants with a DBS sample collected at study visits were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care (SoC)</title>
            <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC)</description>
          </group>
          <group group_id="O2">
            <title>SoC + iTab</title>
            <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC) and daily individualized text-messaging for adherence building (iTAB)</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence to PrEP</title>
          <description>Proportion of participants adherent to PrEP as measured by TFV-DP dried blood spot (DBS) concentrations &gt; 719 fmol/punch at Week 12 and the last on-drug visit.</description>
          <population>Only participants with a DBS sample collected at study visits were included in this analysis.</population>
          <units>% participants with &gt; 719 fmol/punch</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6"/>
                    <measurement group_id="O2" value="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6"/>
                    <measurement group_id="O2" value="83.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Perfect Adherence to PrEP</title>
        <description>Proportion of participants with perfect adherence to PrEP as measured by TFV-DP dried blood spot (DBS) concentrations &gt; 1246 fmol/punch at Week 12 and the last on-drug visit.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Only participants with a DBS sample collected at study visits were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care (SoC)</title>
            <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC)</description>
          </group>
          <group group_id="O2">
            <title>SoC + iTab</title>
            <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC) and daily individualized text-messaging for adherence building (iTAB)</description>
          </group>
        </group_list>
        <measure>
          <title>Perfect Adherence to PrEP</title>
          <description>Proportion of participants with perfect adherence to PrEP as measured by TFV-DP dried blood spot (DBS) concentrations &gt; 1246 fmol/punch at Week 12 and the last on-drug visit.</description>
          <population>Only participants with a DBS sample collected at study visits were included in this analysis.</population>
          <units>% participants with &gt; 1246 fmol/punch</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="181"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9"/>
                    <measurement group_id="O2" value="50.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of HIV Seroconversion</title>
        <description>Determine the rate of HIV seroconversion in PrEP users and compare the iTAB to SOC arms for number of new infections as a proportion at 48 weeks and end of study.</description>
        <time_frame>Up to 2.5 years after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care (SoC)</title>
            <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC)</description>
          </group>
          <group group_id="O2">
            <title>SoC + iTab</title>
            <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC) and daily individualized text-messaging for adherence building (iTAB)</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of HIV Seroconversion</title>
          <description>Determine the rate of HIV seroconversion in PrEP users and compare the iTAB to SOC arms for number of new infections as a proportion at 48 weeks and end of study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to end of follow up for participants 0-120 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care (SoC)</title>
          <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC)</description>
        </group>
        <group group_id="E2">
          <title>SoC + iTab</title>
          <description>Fixed-dose daily oral 300mg tenofovir (TDF) and 200mg emtricitabine (FTC) with Standard of Care (SOC) and daily individualized text-messaging for adherence building (iTAB)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>HIV Seroconversion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Fanconi syndrome</sub_title>
                <description>Related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="198"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI symptoms</sub_title>
                <description>nausea, diarrhea, abdomen pain</description>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="198"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>tonsil lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression with or without sucidality</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>GU symptoms and disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Discontinuation of PrEP may be for valid reasons for not needing prevention of HIV due to not being sexually active</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mike Duszynski</name_or_title>
      <organization>UC San Diego</organization>
      <phone>6195438080</phone>
      <email>mduszynski@health.ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

